NatureWise Biotech & Medicals Corporation
NatureWise Biotech & Medicals Corporation engages in the research and development of Western medicine, Chinese medicine, and biotechnology in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; and green propolis and red yeast rice products. The company was founded in 1990 and is headquartered in Taipei, Taiwan.
NatureWise Biotech & Medicals Corporation (4732) - Total Liabilities
Latest total liabilities as of June 2025: NT$68.06 Million TWD
Based on the latest financial reports, NatureWise Biotech & Medicals Corporation (4732) has total liabilities worth NT$68.06 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NatureWise Biotech & Medicals Corporation - Total Liabilities Trend (2016–2024)
This chart illustrates how NatureWise Biotech & Medicals Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NatureWise Biotech & Medicals Corporation Competitors by Total Liabilities
The table below lists competitors of NatureWise Biotech & Medicals Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WIN HANVERKY
MU:N2R
|
Germany | €1.39 Billion |
|
CyberCatch Holdings Inc.
V:CYBE
|
Canada | CA$1.51 Million |
|
First Hydrogen Corp
PINK:FHYDF
|
USA | $7.15 Million |
|
Alfabs Australia Ltd
AU:AAL
|
Australia | AU$66.95 Million |
|
Alpha Exploration Ltd
V:ALEX
|
Canada | CA$395.82K |
|
Soosung Innovation Co. Ltd.
KQ:084180
|
Korea | ₩137.40 Billion |
|
BCWORLD PHARM. Co. Ltd
KQ:200780
|
Korea | ₩101.30 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down NatureWise Biotech & Medicals Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NatureWise Biotech & Medicals Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NatureWise Biotech & Medicals Corporation (2016–2024)
The table below shows the annual total liabilities of NatureWise Biotech & Medicals Corporation from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$57.03 Million | -12.10% |
| 2023-12-31 | NT$64.89 Million | +27.01% |
| 2022-12-31 | NT$51.09 Million | -36.32% |
| 2021-12-31 | NT$80.22 Million | +33.86% |
| 2020-12-31 | NT$59.93 Million | -18.91% |
| 2019-12-31 | NT$73.90 Million | +75.85% |
| 2018-12-31 | NT$42.03 Million | +43.82% |
| 2017-12-31 | NT$29.22 Million | +161.13% |
| 2016-12-31 | NT$11.19 Million | -- |